These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38107799)

  • 1. Biologic Antiresorptive: Denosumab.
    Kumar L; Arora MK; Marwah S
    Indian J Orthop; 2023 Dec; 57(Suppl 1):127-134. PubMed ID: 38107799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.
    Kendler DL; Cosman F; Stad RK; Ferrari S
    Adv Ther; 2022 Jan; 39(1):58-74. PubMed ID: 34762286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging concepts in the use of denosumab for the treatment of osteoporosis.
    Lewiecki EM
    Ther Adv Musculoskelet Dis; 2018 Nov; 10(11):209-223. PubMed ID: 30386439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
    Varenna M; Gatti D
    Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
    Popp AW; Zysset PK; Lippuner K
    Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
    Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
    Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review.
    Anastasilakis AD; Makras P; Yavropoulou MP; Tabacco G; Naciu AM; Palermo A
    J Clin Med; 2021 Jan; 10(1):. PubMed ID: 33406802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of osteoporosis treatment on bone mass.
    Appelman-Dijkstra NM; Oei HLDW; Vlug AG; Winter EM
    Best Pract Res Clin Endocrinol Metab; 2022 Mar; 36(2):101623. PubMed ID: 35219602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab: an investigational drug for the management of postmenopausal osteoporosis.
    Lewiecki EM
    Biologics; 2008 Dec; 2(4):645-53. PubMed ID: 19707445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in osteoporosis.
    Diab DL; Watts NB
    Expert Opin Drug Saf; 2014 Feb; 13(2):247-53. PubMed ID: 24289327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporosis in men: epidemiology and treatment with denosumab.
    Sidlauskas KM; Sutton EE; Biddle MA
    Clin Interv Aging; 2014; 9():593-601. PubMed ID: 24748777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab - a new medication in the treatment of postmenopausal osteoporosis.
    Słopień R; Rynio P; Kubala E; Milewska E; Meczekalski B
    Prz Menopauzalny; 2017 Sep; 16(3):75-78. PubMed ID: 29507572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab: mechanism of action and clinical outcomes.
    Hanley DA; Adachi JD; Bell A; Brown V
    Int J Clin Pract; 2012 Dec; 66(12):1139-46. PubMed ID: 22967310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL as a target for the treatment of osteoporosis.
    Matsumoto T; Endo I
    J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When and how to stop denosumab therapy in a patient with osteoporosis.
    Goulden EL; Crowley RK
    Clin Endocrinol (Oxf); 2023 May; 98(5):649-653. PubMed ID: 35470448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature.
    Tay WL; Tay D
    Endocrinol Metab (Seoul); 2022 Apr; 37(2):183-194. PubMed ID: 35417954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.